Westhovens, R., Yocum, D., Han, J., Berman, A., Strusberg, I., GEUSENS, Pieter [1196], ...
OBJECTIVE: To assess the risk of serious infections following 22 weeks of infliximab therapy, and to further characterize the safety profile of infliximab in combination with background treatments...
Westhovens, R., Yocum, D., Han, J., Berman, A., Strusberg, I., GEUSENS, Pieter [1196], ...
OBJECTIVE: To assess the risk of serious infections following 22 weeks of infliximab therapy, and to further characterize the safety profile of infliximab in combination with background treatments...
Westhovens, R., Yocum, D., Han, J., Berman, A., Strusberg, I., GEUSENS, Piet, ...
OBJECTIVE: To assess the risk of serious infections following 22 weeks of infliximab therapy, and to further characterize the safety profile of infliximab in combination with background treatments...
Yocum, D, Wolfe, F, Rahman, MU, Han, J, Berman, A, Strusberg, I, ...
Univ Arizona, Tucson, AZ USA. Natl Data Bank Rheum Dis, Wichita, KS USA. Centocor Inc, Malvern, PA 19355 USA. Hosp Angel C Padilla, San Miguel De Tucuman, Argentina. Ctr Reumatol Strusberg, Cordoba,...
Yocum, D, Wolfe, F, Rahman, MU, Han, J, Berman, A, Strusberg, I, ...
Univ Arizona, Tucson, AZ USA. Natl Data Bank Rheum Dis, Wichita, KS USA. Centocor Inc, Malvern, PA 19355 USA. Hosp Angel C Padilla, San Miguel De Tucuman, Argentina. Ctr Reumatol Strusberg, Cordoba,...